These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 23231385)

  • 21. Serotonin1A receptors in the pathophysiology of schizophrenia: development of novel cognition-enhancing therapeutics.
    Sumiyoshi T; Bubenikova-Valesova V; Horacek J; Bert B
    Adv Ther; 2008 Oct; 25(10):1037-56. PubMed ID: 18839076
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting glutamate system for novel antipsychotic approaches: relevance for residual psychotic symptoms and treatment resistant schizophrenia.
    de Bartolomeis A; Sarappa C; Magara S; Iasevoli F
    Eur J Pharmacol; 2012 May; 682(1-3):1-11. PubMed ID: 22387855
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: a proof-of-mechanism study.
    Winterer G; Gallinat J; Brinkmeyer J; Musso F; Kornhuber J; Thuerauf N; Rujescu D; Favis R; Sun Y; Franc MA; Ouwerkerk-Mahadevan S; Janssens L; Timmers M; Streffer JR
    Neuropharmacology; 2013 Jan; 64():197-204. PubMed ID: 22766391
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia.
    Olincy A; Harris JG; Johnson LL; Pender V; Kongs S; Allensworth D; Ellis J; Zerbe GO; Leonard S; Stevens KE; Stevens JO; Martin L; Adler LE; Soti F; Kem WR; Freedman R
    Arch Gen Psychiatry; 2006 Jun; 63(6):630-8. PubMed ID: 16754836
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emerging drugs for schizophrenia.
    Biedermann F; Fleischhacker WW
    Expert Opin Emerg Drugs; 2011 Jun; 16(2):271-82. PubMed ID: 21563991
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Muscarinic agonists and antagonists in schizophrenia: recent therapeutic advances and future directions.
    Bolbecker AR; Shekhar A
    Handb Exp Pharmacol; 2012; (208):167-90. PubMed ID: 22222699
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The neurobiology of cognition in schizophrenia.
    Tamminga CA
    J Clin Psychiatry; 2006; 67 Suppl 9():9-13; discussion 36-42. PubMed ID: 16965183
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Can genetics inform the management of cognitive deficits in schizophrenia?
    Vyas NS; Shamsi SA; Malhotra AK; Aitchison KJ; Kumari V
    J Psychopharmacol; 2012 Mar; 26(3):334-48. PubMed ID: 22328662
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Schizophrenia drug discovery and development in an evolving era: are new drug targets fulfilling expectations?
    Dunlop J; Brandon NJ
    J Psychopharmacol; 2015 Feb; 29(2):230-8. PubMed ID: 25586401
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuronal α7 Nicotinic Receptors as a Target for the Treatment of Schizophrenia.
    Wallace TL; Bertrand D
    Int Rev Neurobiol; 2015; 124():79-111. PubMed ID: 26472526
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nicotinic receptors and schizophrenia.
    Ripoll N; Bronnec M; Bourin M
    Curr Med Res Opin; 2004 Jul; 20(7):1057-74. PubMed ID: 15265251
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glutamatergic neurotransmission modulators as emerging new drugs for schizophrenia.
    Heresco-Levy U
    Expert Opin Emerg Drugs; 2005 Nov; 10(4):827-44. PubMed ID: 16262565
    [TBL] [Abstract][Full Text] [Related]  

  • 33. First administration of cytidine diphosphocholine and galantamine in schizophrenia: a sustained alpha7 nicotinic agonist strategy.
    Deutsch SI; Schwartz BL; Schooler NR; Rosse RB; Mastropaolo J; Gaskins B
    Clin Neuropharmacol; 2008; 31(1):34-9. PubMed ID: 18303489
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential nicotinic regulation of the nigrostriatal and mesolimbic dopaminergic pathways: implications for drug development.
    Janhunen S; Ahtee L
    Neurosci Biobehav Rev; 2007; 31(3):287-314. PubMed ID: 17141870
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [New pharmacological approaches to the treatment of schizophrenia].
    Uzbay IT
    Turk Psikiyatri Derg; 2009; 20(2):175-82. PubMed ID: 19504368
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interactions of nicotine and drugs used in the treatment of mental illnesses with respect to cognitive functions.
    Burda K; Czubak A; Nowakowska E; Kus K; Metelska J; Nowakowska A
    Arzneimittelforschung; 2010; 60(9):527-43. PubMed ID: 21117496
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nicotinic acetylcholine receptors: from basic science to therapeutics.
    Hurst R; Rollema H; Bertrand D
    Pharmacol Ther; 2013 Jan; 137(1):22-54. PubMed ID: 22925690
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nicotinic antagonist effects in the mediodorsal thalamic nucleus: regional heterogeneity of nicotinic receptor involvement in cognitive function.
    Cannady R; Weir R; Wee B; Gotschlich E; Kolia N; Lau E; Brotherton J; Levin ED
    Biochem Pharmacol; 2009 Oct; 78(7):788-94. PubMed ID: 19477167
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Psychopharmacology of the negative symptoms: current status and prospects for progress.
    Davis MC; Horan WP; Marder SR
    Eur Neuropsychopharmacol; 2014 May; 24(5):788-99. PubMed ID: 24252823
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic utility of NK3 receptor antagonists for the treatment of schizophrenia.
    Dawson LA; Smith PW
    Curr Pharm Des; 2010 Jan; 16(3):344-57. PubMed ID: 20109143
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.